Abstract
Lenalidomide is a second generation immunomodulatory agent (IMiD), which currently represents the standard of care for treatment of transfusion dependent lower risk myelodysplastic syndrome (MDS) patients with deletion (5q). Lenalidomide has unique activity with a high transfusion independence rate observed in this subset of patients. In this article we summarize the clinical experience using lenalidomide for treatment of del (5q) MDS. We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS.
Keywords: Lenalidomide, myelodysplastic syndromes, deletion 5q, non-del(5q), immunomodulatory agent (IMiD), bone marrow failure, anemia, cytokines, apoptosis, myeloblast
Current Pharmaceutical Design
Title:Lenalidomide for Treatment of Myelodysplastic Syndromes
Volume: 18 Issue: 22
Author(s): Rami S. Komrokji and Alan F. List
Affiliation:
Keywords: Lenalidomide, myelodysplastic syndromes, deletion 5q, non-del(5q), immunomodulatory agent (IMiD), bone marrow failure, anemia, cytokines, apoptosis, myeloblast
Abstract: Lenalidomide is a second generation immunomodulatory agent (IMiD), which currently represents the standard of care for treatment of transfusion dependent lower risk myelodysplastic syndrome (MDS) patients with deletion (5q). Lenalidomide has unique activity with a high transfusion independence rate observed in this subset of patients. In this article we summarize the clinical experience using lenalidomide for treatment of del (5q) MDS. We highlight the mechanism of action and the recent advances in understanding the biology of del (5q) MDS. We also explore its potential use and the efforts to further improve its activity in non-del (5q) MDS.
Export Options
About this article
Cite this article as:
S. Komrokji Rami and F. List Alan, Lenalidomide for Treatment of Myelodysplastic Syndromes, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023198
DOI https://dx.doi.org/10.2174/1381612811209023198 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Inflammaging of Female Reproductive System: A Molecular Landscape
Current Aging Science Clinical Experience of Non-Invasive Prenatal Chromosomal Aneuploidy Testing in 190,277 Patient Samples
Current Molecular Medicine Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Editorial (Thematic Issues: Pharmacological Intervention for Down Syndrome Cognitive Deficits: Emerging Drug Targets)
CNS & Neurological Disorders - Drug Targets CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes
Current Pharmaceutical Design New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets MALDI-ToF Mass Spectra Phenomic Analysis for Human Disease Diagnosis Enabled by Cutting-Edge Data Processing Pipelines and Bioinformatics Tools
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Regenerative Medicine Biologic Characteristics of Bone Marrow Mesenchymal Stem Cells in Myelodysplastic Syndromes
Current Stem Cell Research & Therapy Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Replicative Senescence: The Final Stage of Memory T Cell Differentiation?
Current HIV Research